CRNX Crinetics Pharmaceuticals, Inc.
CRNX Crinetics Pharmaceuticals, Inc.
Healthcare · Biotechnology
No longer tracked since 2026-09-03 — left the market.
Market read
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Reported EPS $-1.14 versus analyst consensus of $-1.18 (+3.7%).
full note →Against street estimates
How CRNX's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.
CRNX research tape
35 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.